​

​

The company was founded in 2007 by well-known Hungarian scientists, Prof. Tamas Freund, Prof. Jozsef Haller and the Hungarian Academy of Sciences.   They started a research by utilizing governmental and EU grant to gain better understanding of the anxiolytic effects of certain herbs and compounds.  In the research process special emphasis were given to the endocannabinoid system, CB1 and CB2 receptors. ​They found that ingredients of a certain kind of Echinacea has anxiolytic effects.  The effect highly depends on the type of plant, where it is grown, which part of the plant is used and how it is processed.  

​​

Professional scientific articles have been published about the anxiolytic effects of Echinacea and international patents have been filed by the founding scientists of the company. The company has screened lots of suppliers and only few were safely able to supply raw materials for the production. Scientific methods have been developed to ensure that the final products always have the right quantity of active ingredients responsible for the anxiolytic effect, as some ingredients in Echinacea might even increase anxiety. 

​

In 2009 together with a reputable GMP certified pharma manufacturer (ExtractumPharma) the company developed EP107™ dietary supplement and started production of the 20mg EP107™ minipills in pharma quality.

​

​Numerous animal and human clinical trials have been completed to prove that EP107™ - without side effects-, is ameliorating sub-threshold and mild anxiety, which are clear risk factors in development of anxiety disorders and depression.

​

In 2010 the first products were sold in the US market under Anxiofit brand, which was later rebranded to AnxioCalm and is exclusively distributed by Europharma Inc.

​

In 2016 the AnxioCalm product received licenses for distribution also in Canada.

​

Anxiofit is currently working on receiving an EFSA approval to be able to use its anti-anxiety health claim on the labels also in the European countries. Final approval is expected to be received in 2021.

PRODUCTS

The small tablet formulation of Anxiofit is mainly based on a special blend of Echinacea extracts gathered from selected growing areas with a unique profile of active principles, which bind to the CB1 cannabinoid receptors in the endocannabinoid system, sustainably reducing anxiety and stress. 

All products include the clinically validated EP107™ ingredient, which is a patent protected, fast acting, non-sedative anxiolytic.

​

Sub-threshold and mild anxiety symptoms are well known risk factors of anxiety disorders and depression. EP107™ decreases the risk factor associated with developing anxiety disorders and depression by ameliorating sub-threshold and mild symptoms of anxiety.

All batches has an extra layer of quality control with proprietary analytics to ensure that the active principles responsible for the anxiolytic effect are present in the right proportion and ingredients in echinacea, which might actually cause anxiety are always present below a minimal threshold.

Upon request reports of clinical trials are available, showing the anxiolytic effect of the products. The outcome measures used to assess this effect were the State-Trait Anxiety Inventory by Spielberger.

ANXIOFIT CLASSIC

AnxioFit original 7mm diameter, 120 mg coated tablets manufactured in Hungary in pharma quality. Tablets contain 20mg EP107™.

ANXIOFIT

VEGAN

Vegan formulation, 8mm diameter coated tablets, without lactose and talc with 40mg EP107™.

ANXIOFIT

HERBAL

Vegan formulation including extra Vitamin B6 and Matricaria Recutita in 8mm diameter coated tablets, containing 40mg EP107™.